FI112325B - Menetelmä laastarin valmistamiseksi, jolla voidaan ihon läpi antaa haihtuvia, farmaseuttisesti vaikuttavia, kemiallisesti emäksisiä aineosia - Google Patents
Menetelmä laastarin valmistamiseksi, jolla voidaan ihon läpi antaa haihtuvia, farmaseuttisesti vaikuttavia, kemiallisesti emäksisiä aineosia Download PDFInfo
- Publication number
- FI112325B FI112325B FI951887A FI951887A FI112325B FI 112325 B FI112325 B FI 112325B FI 951887 A FI951887 A FI 951887A FI 951887 A FI951887 A FI 951887A FI 112325 B FI112325 B FI 112325B
- Authority
- FI
- Finland
- Prior art keywords
- layer
- matrix
- foil
- patch
- adhesive
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 4
- 239000000470 constituent Substances 0.000 title claims description 5
- 239000011159 matrix material Substances 0.000 claims abstract description 42
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims abstract description 16
- 239000012458 free base Substances 0.000 claims abstract description 11
- 239000004615 ingredient Substances 0.000 claims abstract description 6
- 239000011888 foil Substances 0.000 claims description 30
- 230000001070 adhesive effect Effects 0.000 claims description 19
- 239000000853 adhesive Substances 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000003085 diluting agent Substances 0.000 claims description 9
- 229920000728 polyester Polymers 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 239000002585 base Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229920003002 synthetic resin Polymers 0.000 claims description 3
- 239000000057 synthetic resin Substances 0.000 claims description 3
- 239000002998 adhesive polymer Substances 0.000 claims description 2
- 238000010030 laminating Methods 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 229920003023 plastic Polymers 0.000 claims 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 abstract 2
- 239000010410 layer Substances 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- -1 for example Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Polymers 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- NFHVTCJKAHYEQN-UHFFFAOYSA-N amfetaminil Chemical compound C=1C=CC=CC=1C(C#N)NC(C)CC1=CC=CC=C1 NFHVTCJKAHYEQN-UHFFFAOYSA-N 0.000 description 2
- 229950000762 amfetaminil Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012229 microporous material Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 2
- 229960003946 selegiline Drugs 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- MPVXINJRXRIDDB-VCDGYCQFSA-N dodecanoic acid;(2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCCCCCC(O)=O MPVXINJRXRIDDB-VCDGYCQFSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-M malonate(1-) Chemical compound OC(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-M 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-M succinate(1-) Chemical compound OC(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-M 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92118036 | 1992-10-22 | ||
| EP92118036A EP0593807A1 (en) | 1992-10-22 | 1992-10-22 | Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation |
| PCT/EP1993/002899 WO1994008571A2 (de) | 1992-10-22 | 1993-10-20 | Pflaster zur transdermalen verabreichung von flüchtigen, pharmazeutisch wirksamen, chemisch basischen inhaltsstoffen und verfahren zu seiner herstellung |
| EP9302899 | 1993-10-20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI951887A0 FI951887A0 (fi) | 1995-04-20 |
| FI951887A7 FI951887A7 (fi) | 1995-04-20 |
| FI112325B true FI112325B (fi) | 2003-11-28 |
Family
ID=8210159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI951887A FI112325B (fi) | 1992-10-22 | 1995-04-20 | Menetelmä laastarin valmistamiseksi, jolla voidaan ihon läpi antaa haihtuvia, farmaseuttisesti vaikuttavia, kemiallisesti emäksisiä aineosia |
Country Status (24)
| Country | Link |
|---|---|
| EP (2) | EP0593807A1 (cs) |
| JP (1) | JP3731016B2 (cs) |
| KR (1) | KR100261913B1 (cs) |
| AT (1) | ATE165001T1 (cs) |
| AU (1) | AU674902B2 (cs) |
| CA (1) | CA2146645C (cs) |
| CZ (1) | CZ290122B6 (cs) |
| DE (1) | DE59308413D1 (cs) |
| DK (1) | DK0665745T3 (cs) |
| ES (1) | ES2116572T3 (cs) |
| FI (1) | FI112325B (cs) |
| HR (1) | HRP931308A2 (cs) |
| HU (1) | HU221594B (cs) |
| IL (1) | IL107360A (cs) |
| MY (1) | MY109783A (cs) |
| NO (1) | NO311404B1 (cs) |
| NZ (1) | NZ257829A (cs) |
| PH (1) | PH30790A (cs) |
| PL (1) | PL173552B1 (cs) |
| SI (1) | SI9300559A (cs) |
| SK (1) | SK51595A3 (cs) |
| WO (1) | WO1994008571A2 (cs) |
| YU (1) | YU48350B (cs) |
| ZA (1) | ZA937807B (cs) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4433191A1 (de) * | 1994-09-17 | 1996-03-21 | Lohmann Therapie Syst Lts | Selbstklebendes Pflaster zur Abgabe von Wirkstoff an die Umgebung eines Trägers |
| US6033682A (en) | 1995-01-13 | 2000-03-07 | Somerset Pharmaceuticals, Inc. | S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions |
| US6319954B1 (en) | 1995-01-13 | 2001-11-20 | Somerset Pharmaceuticals, Inc. | S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions |
| US6299901B1 (en) | 1995-01-13 | 2001-10-09 | Somerset Pharmaceuticals, Inc. | Methods and pharmaceutical compositions employing desmethylselegiline |
| US6348208B1 (en) | 1995-01-13 | 2002-02-19 | Somerset Pharmaceuticals, Inc. | Methods and pharmaceutical compositions employing desmethylselegiline |
| JPH11506744A (ja) * | 1995-06-07 | 1999-06-15 | ノウブン ファーマシューティカルズ インク． | 室温で液体である低分子量薬を含む経皮組成物 |
| US6316022B1 (en) | 1995-06-07 | 2001-11-13 | Noven Pharmaceuticals, Inc. | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| WO1997006788A1 (en) * | 1995-08-14 | 1997-02-27 | Janssen Pharmaceutica N.V. | Transdermal administration of vorozole |
| DE19533772C1 (de) * | 1995-09-12 | 1998-01-02 | Hexal Ag | Tacrin/Selegilin-Pflaster |
| US7150881B2 (en) | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
| DE19733981A1 (de) * | 1997-08-06 | 1999-02-11 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System (TTS) zur Abgabe von Wirkstoff durch die Haut an einen Organismus und Verfahren zur Applikation auf der Haut |
| AU9553398A (en) * | 1997-11-04 | 1999-05-24 | Clear Sport Ltd | Improvements relating to adhesive devices such as strips, tapes, patches and thelike, for application to the human body |
| DE69902520T2 (de) | 1998-03-16 | 2003-04-10 | Somerset Pharmaceuticals, Inc. | Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden |
| DE19814083C2 (de) | 1998-03-30 | 2002-02-07 | Lohmann Therapie Syst Lts | Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen |
| DE19814257A1 (de) | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Brauseformulierungen |
| DE19826592A1 (de) * | 1998-06-15 | 1999-12-16 | Lohmann Therapie Syst Lts | Verfahren zur Herstellung eines aus einzelnen Schichten bestehenden Laminats |
| DE19950066A1 (de) * | 1999-10-16 | 2001-04-26 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit einem Gehalt an Tulobuterol-hydrochlorid zur Verabreichung des Bronchodilatators Tulobuterol über die Haut |
| ATE427745T1 (de) | 2001-11-05 | 2009-04-15 | Krele Pharmaceuticals Llc | Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus |
| EP2167002B1 (en) | 2007-07-10 | 2016-04-20 | Agile Therapeutics, Inc. | Dermal delivery device with in situ seal |
| US20100087768A1 (en) | 2008-10-02 | 2010-04-08 | Forlano Paula | Transdermal drug delivery system for liquid active ingredient |
| EP2563347B1 (en) | 2010-04-30 | 2016-10-12 | Teikoku Pharma USA, Inc. | Propynylaminoindan transdermal compositions |
| KR101853082B1 (ko) * | 2011-03-24 | 2018-04-27 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 활성제층 및 활성제 변환층을 포함하는 경피 조성물 |
| SG11201502681WA (en) | 2012-11-02 | 2015-05-28 | Teikoku Pharma Usa Inc | Propynylaminoindan transdermal compositions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| GB8807504D0 (en) * | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
-
1992
- 1992-10-22 EP EP92118036A patent/EP0593807A1/en not_active Withdrawn
-
1993
- 1993-09-20 PH PH46901A patent/PH30790A/en unknown
- 1993-09-23 MY MYPI93001931A patent/MY109783A/en unknown
- 1993-10-19 HR HR931308A patent/HRP931308A2/hr not_active Application Discontinuation
- 1993-10-20 AU AU54627/94A patent/AU674902B2/en not_active Ceased
- 1993-10-20 CZ CZ19951022A patent/CZ290122B6/cs not_active IP Right Cessation
- 1993-10-20 JP JP50965794A patent/JP3731016B2/ja not_active Expired - Fee Related
- 1993-10-20 WO PCT/EP1993/002899 patent/WO1994008571A2/de not_active Ceased
- 1993-10-20 PL PL93308292A patent/PL173552B1/pl not_active IP Right Cessation
- 1993-10-20 DK DK94900072T patent/DK0665745T3/da active
- 1993-10-20 EP EP94900072A patent/EP0665745B1/de not_active Expired - Lifetime
- 1993-10-20 SK SK515-95A patent/SK51595A3/sk unknown
- 1993-10-20 KR KR1019950701535A patent/KR100261913B1/ko not_active Expired - Fee Related
- 1993-10-20 NZ NZ257829A patent/NZ257829A/en not_active IP Right Cessation
- 1993-10-20 HU HU9501125A patent/HU221594B/hu not_active IP Right Cessation
- 1993-10-20 DE DE59308413T patent/DE59308413D1/de not_active Expired - Lifetime
- 1993-10-20 CA CA002146645A patent/CA2146645C/en not_active Expired - Fee Related
- 1993-10-20 AT AT94900072T patent/ATE165001T1/de active
- 1993-10-20 ES ES94900072T patent/ES2116572T3/es not_active Expired - Lifetime
- 1993-10-21 YU YU67293A patent/YU48350B/sh unknown
- 1993-10-21 ZA ZA937807A patent/ZA937807B/xx unknown
- 1993-10-21 IL IL107360A patent/IL107360A/en not_active IP Right Cessation
- 1993-10-22 SI SI9300559A patent/SI9300559A/sl unknown
-
1995
- 1995-04-20 FI FI951887A patent/FI112325B/fi not_active IP Right Cessation
- 1995-04-21 NO NO19951523A patent/NO311404B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI112325B (fi) | Menetelmä laastarin valmistamiseksi, jolla voidaan ihon läpi antaa haihtuvia, farmaseuttisesti vaikuttavia, kemiallisesti emäksisiä aineosia | |
| US5462746A (en) | Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation | |
| KR100300477B1 (ko) | 활성성분으로서 갈란타민을 포함하는 경피치료시스템 | |
| US5730999A (en) | Dermal therapeutic system made of a meltable poly (meth) acrylate | |
| US5306503A (en) | Patch with a high content of softening ingredients | |
| US9295655B2 (en) | Fentanyl transdermal patch | |
| US20180256562A1 (en) | Transdermal Delivery System | |
| FI118885B (fi) | Skopolamiinilaastari | |
| JP2003515555A (ja) | 同一有効成分を含有する貯留部と基質部を備えた経皮投与部材 | |
| KR20140111617A (ko) | 약물의 경피 흡수 촉진용 조성물 및 패치 제제 | |
| WO2020092990A1 (en) | Pharmaceutical compositions and methods of making a patch formulation for transdermal delivery | |
| EP1352649A2 (en) | Patch and production method thereof | |
| CA2602534C (en) | Transdermal patch | |
| CN113382724A (zh) | 贴剂 | |
| US8968774B2 (en) | Preparation and composition of meloxicam transdermal drug delivery system | |
| EP1711170B1 (en) | Transdermal delivery device for dihydropyridine type calcium antagonists containing two fatty acids | |
| PL172999B1 (pl) | Terapeutyczny system przezskórny (TTS) do podawania fizostygminy na skórę i sposób wytwarzania terapeutycznego systemu przezskórnego do podawania fizostygminy na skórę | |
| JPH06279288A (ja) | パップ剤 | |
| JPH10316825A (ja) | 粘着性組成物 | |
| KR20020066047A (ko) | 케토프로펜을 함유하는 경피투여 조성물과 이를 포함하는매트릭스형 경피투여 첩부제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |